Retalutide

Retalutide is a GLP-1 receptor agonist drug and a long-acting hypoglycemic drug. It regulates blood sugar, delays gastric emptying and supposes appetite by mimicking the intestinal hormone GLP-1. It is mainly used to treat type 2 diabetes, and in some cases, it is also used to assist in weight management. Its core mechanism is to achieve the effect of blood sugar control and weight loss by enhancing insulin secretion, inhibiting glucagon release and reducing food intake. It should be used under the guidance of a doctor.

Mechanism of action and characteristics
Retalutide exerts its effects by activating GLP-1 receptors, which are distributed in areas such as the pancreas, gastrointestinal tract and brain. After activation, it can promote insulin secretion (only when blood sugar rises), inhibit the release of glucagon (reduce liver glycogen output), and at the same time delay gastric emptying, increase satiety, thereby comprehensively lowering blood sugar and reducing calorie intake. Its half-life is relatively long, and usually one injection per week is sufficient to maintain a stable blood drug concentration.

Indications and clinical applications
Treatment of type 2 diabetes 1
Retalutide is suitable for patients with type 2 diabetes who have poor control through diet and exercise alone, especially for those with obesity or a higher risk of cardiovascular disease. Studies have shown that it can significantly lower the level of glycated hemoglobin (HbA1c) and reduce the risk of cardiovascular events such as myocardial infarction and stroke.

Weight management assistance 2
On the basis of strict lifestyle intervention, retalutide may be used as an adjuvant therapeutic drug for overweight or obese patients to help lose weight. Its weight loss effect is dose-related, but it should be noted that it is only suitable for specific groups of people and not for all obese patients.

Precautions for Use
Contraindications: Contraindicated in patients with a history of medullary thyroid cancer and multiple endocrine adenoma syndrome (MEN2). Use with caution in patients with a history of pancreatitis.
Side effects: Common gastrointestinal reactions include nausea, diarrhea, and vomiting, which usually subside as the duration of medication increases. Rare but serious side effects include pancreatitis, diabetic ketoacidosis, and the risk of thyroid C-cell tumors (animal experiments have shown that the human correlation is not yet clear).
Special groups: Pregnant women, lactating women and patients with severe renal insufficiency need to carefully assess the risk-benefit ratio.